Neurotrauma induced retinal basement membrane COL4A1 defects are restored by adipose tissue derived mesenchymal stem cell concentrated conditioned medium.
Rasiah PK., Jha KA., Gentry J., Del Mar NA., Pfeffer LM., Reiner A.
Case Report / Series on Chronic Inflammation, published in Stem Cell Res Ther (2025) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Case Report / Series
- Journal
- Stem Cell Res Ther (2025)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 41398913
- DOI
- 10.1186/s13287-025-04804-6
Abstract (original English)
COL4A1 defects are known to cause a variety of multisystem disorders with significant vascular dysfunction leading to neuronal damage. Case reports suggest that patients with COL4A1 mutations or extracellular COL4A1 deficiency in the basement membrane may put individuals at increased risk for developing visual deficits with neurotrauma. However, no experimental evidence is available. This study investigated the impact of Col4a1 deficiency on visual dysfunction following mild traumatic brain injury (mTBI) and evaluated the therapeutic efficacy of COL4A1-enriched adipose-derived stem cell-conditioned medium (ASC-CCM) in mitigating associated neurovascular deficits. Using a retina-targeted knockdown approach in C57Bl/6 mice via intravitreal delivery of AAV2-Col4a1 shRNA, followed by a controlled 50-psi air-blast to induce mTBI, we assessed visual performance, retinal histopathology, and gene expression profiles for 4 weeks post-injury. Treatment with ASC-CCM was administered intravitreally post-blast. In-vitro, Col4a1 knockdown in human retinal endothelial cells (HRECs) assessed the therapeutic benefit of COL4A1-enriched ASC-CCM. After blast injury, Col4a1-deficient mice displayed significantly greater reductions in visual acuity and contrast sensitivity thresholds compared to control mice, which were substantially restored following ASC-CCM treatment. Histological and molecular a
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • Without an adequate control group, treatment effects cannot be separated from other factors.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewEurope PMC
Comparing Regenerative Biologics and Standard Pharmacotherapy for Chronic Rotator Cuff Tendinopathy: A Study of PRP, Cell-Based, and Peptide Interventions
Systematic Review on Tendon Injury, Rotator Cuff, Shoulder Pain, Chronic Inflammation, published in J Orthop Sports Med (2026) — summary generated from the PubMed abstract.
- 2026
J Orthop Sports Med - Level ASystematic ReviewEurope PMC
Harnessing exosomes in dry eye disease: a triple threat approach
Systematic Review on Neuroinflammation, Chronic Inflammation, Immune Modulation, published in BMC Ophthalmol (2026) — summary generated from the PubMed abstract.
- 2026
BMC Ophthalmol - Level AMeta-analysisPubMed
Comparative efficacy of different doses of mesenchymal stem cells derived from different tissue sources for knee osteoarthritis: a systematic review and network meta-analysis of randomized controlled trials.
Meta-analysis with a reported sample of 602 on Knee Osteoarthritis, Osteoarthritis, Chronic Inflammation, Immune Modulation, published in PeerJ (2026) — summary generated from the PubMed abstract.
- 2026
- n = 602
PeerJ - Level ASystematic ReviewEurope PMC
Exosomes as Cellular Communicators and Therapeutic Agents in Orthopedic Diseases: From Mechanisms to Intervention
Systematic Review on Osteoarthritis, Chronic Inflammation, published in Int J Nanomedicine (2026) — summary generated from the PubMed abstract.
- 2026
Int J Nanomedicine1 citations - Level ASystematic ReviewEurope PMC
Pharmacotherapy agents in prevention and treatment of breast cancer-related lymphedema: a systematic scoping review
Systematic Review on Chronic Inflammation, Immune Modulation, published in Front Oncol (2026) — summary generated from the PubMed abstract.
- 2026
Front Oncol - Level ASystematic ReviewEurope PMC
Trends in peripheral nerve injury research: a bibliometric analysis focused on molecular mechanisms
Systematic Review on Chronic Inflammation, published in Front Neurol (2026) — summary generated from the PubMed abstract.
- 2026
Front Neurol